The present disclosure provides a method for determining the level of expression of one or more lineage markers in a blood sample, such as circulating tumor cells (CTC), tumor-specific exosomes, or tumor-specific in a subject's blood sample. A new assay method for analyzing RNA derived from natural cell-free RNA, wherein the expression level of a particular one or more phylogenetic markers is assessed as progression-free survival and overall survival for a particular anti-cancer treatment regimen in the subject For assays that are predictive of time.
展开▼
